-
Tens of billions of gold track, BTK inhibitor research and development ushered in a new strategy
Time of Update: 2022-12-30
At present, its R&D strategy mainly includes the development of non-covalent BTK inhibitors and BTK PROTACs. 01 Non-covalent BTK inhibitors01 Non-covalent BTK inhibitorsNon-covalent BTK inhibitors do not rely on binding to the C481 site, but bind to the BTK protein by hydrogen bonding, so they are expected to effectively overcome the resistance problems in the previous generation of products.
-
Annual Inventory In 2022, these 14 Class 1 new drugs were approved in China
Time of Update: 2022-12-30
First-line treatment of inoperably advanced or metastatic squamous non-small cell lung cancer (NSCLC) significantly prolongs PFS in patients with higher ORR and longer duration of response (DoR)Pfizer: AlbuxitinibPfizer: AlbuxitinibMode of action: JAK1 inhibitorMode of action: JAK1 inhibitorIndications: atopic dermatitisIndications: atopic dermatitisIn April this year, Pfizer's oral JAK1 inhibitor albuxitinib tablets were approved for marketing in China for the treatment of moderate to severe atopic dermatitis in adults.
-
Annual inventory: the world's top ten new blockbuster innovative drugs in 2022
Time of Update: 2022-12-30
Indications:On January 28, 2022, the FDA approved the marketing of Roche's new drug Vabysmo, and in September of the same year, based on the good results of phase III clinical trials, the European Commission (EC) also approved the marketing of the drug for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), thereby improving vision to some extent.
-
CSCO-CDE session: Antitumor drug involution is in remission | first scene
Time of Update: 2022-12-30
At present, the research and development of anti-tumor drugs in China is in a period of vigorous development. According to the drug clinical trial registration and information disclosure platform, the
-
2022, Survival Atlas of PD-(L)1 in China
Time of Update: 2022-12-30
Indications "Exclusivity"In terms of indications "broad (large indications)",Indications "Broad (large indications)"Innovent (Cindilimab) includes two lung cancers, one liver cancer, and one gastric cancer;BeiGene (tislelizumab) includes three lung cancers, one liver cancer;Hengrui Pharma (carrelizumab) includes two lung cancers and one liver cancer;Junshi Biologics (teripulimab) includes one count of lung cancer;Specific number of indications:Specific number of indications:Different from the world, in the Chinese market, entering medical insurance is an important way to achieve rapid product volume.
-
【Hot spot】Just now, Academician Zhong Nanshan's lecture brushed the screen! Respond to hot topics!
Time of Update: 2022-12-30
Zhong Nanshan said that in contrast, the incubation period in the north is further shortened, sometimes symptoms appear after the second day of exposure, most people do not have obvious symptoms after infection, and some people have dry throat headache and fever.
-
Not defeated by the new crown, but entered the ICU because of indiscriminate medication?
Time of Update: 2022-12-30
At the same time, after having a disease, you can not buy your own medicine, the correct way is to go to the hospital, determine the cause, and use the drug according to the doctor's guidance.
-
Courier About $28 billion to get a number of marketed therapies! Amgen acquires Horizon
Time of Update: 2022-12-30
” Original: _mstmutation="1" _msthash="220728" _msttexthash="10020946"> On December 12, Amgen announced that it has reached an agreement with Horizon Therapeutics to acquire the latter for about $28 billion.
-
Today, Hong Kong stocks welcome biopharmaceutical companies, and the CEO is a former FDA new drug review expert
Time of Update: 2022-12-30
At the same time, it can be noted that at the beginning of December, in addition to Sidi Pharmaceutical, all biopharmaceutical companies with new IPO developments in the Hong Kong Stock Exchange include: Youzhiyou Biotechnology, a bispecific antibody drug R&D and production company, has submitted an IPO application to the Hong Kong Stock Exchange, and Boan Biotechnology, a subsidiary of Luye Pharmaceutical, has passed the listing hearing of the Hong Kong Stock Exchange, and so on.
-
Boston Scientific's $500 million acquisition of Syntruda, the acceleration of localization integration, what enlightenment does it bring to domestic biotech?
Time of Update: 2022-12-30
Therefore, the importance of the "localization" strategy has become more and more prominent, and multinational enterprises that want to take a share in the Chinese market have begun to accelerate the layout of mergers and acquisitions, especially in the field of medical devices.
-
The stock prices of Yiling Pharmaceutical, Northeast Pharmaceutical, Xinhua Pharmaceutical, etc. soared in December! How long can the "hoarding market" last?
Time of Update: 2022-12-30
Recently, the market demand for antipyretic and analgesic drugs has exploded, and Xinhua Pharmaceutical, the leading A-share ibuprofen API, is hot, with a stock price of 8 boards in 10 days, a five-day increase of 83.
-
The French Food and Drug Administration is under investigation for handling changes in thyroid drug formulations
Time of Update: 2022-12-30
The company explained that this formulation change was made at the request of the French National Agency for the Safety of Medicines and Health Products (ANSM) and that the new formula is bioequivalent to the original formulation.
-
There is a bug! OK mirror collection and procurement rules released, another tragedy?
Time of Update: 2022-12-30
The BUG of Hebei Centralized Procurement: It only focuses on the product itself, ignoring the service fee of medical institutions and the cost of derivative productsThe Hebei centralized procurement document clarifies that the price declared by OK mirror manufacturers must include all expenses such as product design, production, packaging, insurance, transportation, distribution, testing, taxes, acceptance, after-sales service, and accompanying services.
-
Gene therapy can cure disease, but can we afford it?
Time of Update: 2022-12-30
AHIP, which represents more than 1,300 companies that provide health insurance to 200 million Americans, said its members are not averse to paying for gene therapy drugs as long as they prove effective and worthwhile.
-
In the past 5 years, the FDA has approved 5 new drugs for DMD, which will enter China through different routes
Time of Update: 2022-12-30
In the past 5 years, the FDA has approved a total of 5 DMD drugs, all of which will enter China through different routes:In the past 5 years, the FDA has approved a total of 5 DMD drugs, all of which
-
The State Food and Drug Administration announced the second batch of drug rule of law publicity and education bases [three-minute quick overview of one-week medical highlights]
Time of Update: 2022-12-30
December 7 - December 13December 7 - December 13These developments in the pharmaceutical industry are worth paying attention toCover NewsCover NewsThe State Food and Drug Administration announced the second batch of drug rule of law publicity and education bases.
-
With multimillion-dollar gene therapies priced at every turn, how do the developers plan to sell them?
Time of Update: 2022-12-30
From Novartis' $2. 1 million Zolgensma, to Bluebird Bio's $2. 8 million Zolgensma and $3 million Skysona, to CSL Behring With $3. 5 million in Hemgenix, we marvel at the ever-refreshing record for "th
-
2022ASH Express; Kangfeng Biologics products were recognized as breakthrough devices by the FDA; Henlius is licensed by Yilian Biologics ADC platform
Time of Update: 2022-12-30
Pharmacis SelectionPharmacis SelectionASH 2022: Ascentage Pharma announces latest data on APG-2575 for the treatment of CLL/SLL patientsASH 2022: Ascentage Pharma announces latest data on APG-2575 for the treatment of CLL/SLL patientsAscentage Pharma Group announced that APG-2575 alone or in combination with CALQUENCE (acalabrutinib) and rituximab in the treatment of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is initially available.
-
Nearly $4 billion in gambling, revealing the top ten licenses in 2022
Time of Update: 2022-12-30
On May 2, Hansen Pharmaceutical reached a strategic cooperation agreement with NiKang to introduce the commercialization rights of the latter's core product NKT2152 in China.
On May 2, Hansen Pharmaceutical reached a strategic cooperation agreement with NiKang to introduce the commercialization rights of the latter's core product NKT2152 in China.
-
The domestic vaccine has been declared to be equivalent to the Pfizer mRNA vaccine, do we have more options?
Time of Update: 2022-12-30
The head-to-head trial of the new crown vaccine in China Cell includes people who have received 2-3 doses of inactivated vaccine or Pfizer mRNA vaccine.
The head-to-head trial of the new crown vaccine in China Cell includes people who have received 2-3 doses of inactivated vaccine or Pfizer mRNA vaccine.
